Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Medipost Co. on the deal. Medipost Co. announced its strategic agreement with OmniaBio, Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
You must be a Standard 1 Year member to access this content.
